The global pharmaceutical market was impacted by a significant disruption after an unanticipated announcement made late on Thursday night by US President Donald Trump.
Starting October 1, all branded and patent drugs imported to the United States are subjected to a 100% tariff. This policy is intended as an incentive for domestic production.
The market reaction to the widespread selling of pharmaceutical stocks on Friday was not the same.
Some companies saw their shares fall by more than 5%.
The sector was relatively stable in Europe, however, as most of the major companies, such as Novartis, GSK and others, saw only minor losses.
The divergence between the Asian and EU businesses suggests that they are prepared to deal with new tariffs in very different ways.
What are the effects of pharma tariffs on European pharmaceutical manufacturers?
Strategic decisions taken well in advance of the news about tariffs may explain why European pharmaceutical stocks have a relatively low response.
Since President Trump’s second term, many of the continent’s largest drug exporters made significant manufacturing investments in the United States.
Exemptions are given to companies that build US-based plants.
The forward-thinking strategy has been a crucial defense.
AstraZeneca’s shares, for example, traded marginally higher Friday, after the company pledged to invest $50 billion in the US by 2030.
Roche’s shares were flat and it announced that the company would inject $50 billion in to the country within five years. It expects to create 12,000 jobs, both for manufacturing and research.
Novartis Switzerland, which committed $23 billion dollars to its US presence also closed up.
As Pascal Soriot, CEO of AstraZeneca noted in August: “Our investment reflects our belief that this country will grow.” “We want to make a contribution to this.”
A spokesperson for the EU Commission described the recent agreement as “insurance.”
What are the effects of pharma tariffs on Asian drugmakers?
Market reaction on Friday in Asia was much more intense, reflecting an increased level of uncertainty about the effect of the new tariffs.
The exact impact on different companies in the region is still unclear, despite the fact that the region accounts for over 20 percent of US imports by volume.
Analysts are generally of the opinion that this sector will not be hit by the full impact of tariffs.
Louise Loo of Oxford Economics’ Asia Economics department predicts the US is likely to issue further announcements describing specific protections for product categories, effectively reducing the tariff burden.
Moreover, Asian countries are not equally affected. Japan and South Korea are exempted due to trade agreements.
India is a key player on the world market and will likely avoid an additional tariff, as the majority of its exports are generics, which generally are not included in the announcement that targets branded or patented products.
Singapore faces the greatest risk, as it specializes in expensive patented drugs, unless companies act quickly to obtain exemptions through active US manufacturing investment.
Investors are adjusting their stock markets to reflect this unequal vulnerability, and they have time for the companies in that region to adapt.
As new information becomes available, this post Trump’s Pharma Tariffs: Why they will hit Europe and Asia in different ways may be updated.
This site is for entertainment only. Click here to read more
